Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Beta Blockers can Mask not only Hypoglycemia but also Hypotension

Author(s): Goran Koracevic, Sladjana Micic, Milovan Stojanovic*, Radmila Velickovic Radovanovic, Milan Pavlovic, Tomislav Kostic, Dragan Djordjevic, Nebojsa Antonijevic, Maja Koracevic, Vesna Atanaskovic and Sonja Dakic

Volume 28, Issue 20, 2022

Published on: 28 June, 2022

Page: [1660 - 1668] Pages: 9

DOI: 10.2174/1381612828666220421135523

Price: $65

Abstract

Background: Beta-adrenergic (β-AR) receptor blockers (BBs) are an essential class of drugs as they have numerous indications. On the other hand, they have numerous unwanted effects that decrease the compliance, adherence, and persistence of this very useful group of drugs.

Objective: The paper aims to analyze the possibility that an unnoticed side effect may contribute to a less favorable pharmacologic profile of BBs, e.g., a diminished reaction to a sudden fall in BP.

Methods: We searched two medical databases for abstracts and citations (Medline and SCOPUS). Moreover, we searched the internet for drug prescription leaflets (of the individual BBs).

Results: Whichever cause of stress is considered, the somatic manifestations of stress will be (partially) masked if a patient takes BB. Stress-induced hypercatecholaminemia acts on β-AR of cardiomyocytes; it increases heart rate and contractility, effects suppressed by BBs. The answers of the organism to hypoglycemia and hypotension share the main mechanisms such as sympathetic nervous system activation and hypercatecholaminemia. Thus, there is a striking analogy: BBs can cover up symptoms of both hypoglycemia (which is widely known) and of hypotension (which is not recognized). It is widely known that BBs can cause hypotension. However, they can also complicate recovery by spoiling the defense mechanisms in hypotension as they interfere with the crucial compensatory reflex to increase blood pressure in hypotension.

Conclusion: Beta blockers can cause hypotension, mask it, and make recovery more difficult. This is clinically important and deserves to be more investigated and probably to be stated as a warning.

Keywords: Beta blockers, arterial hypotension, hypoglycemia, side effects, adherence, heart failure.

« Previous Next »
[1]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[2]
Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 2019; 42(9): 1235-481.
[http://dx.doi.org/10.1038/s41440-019-0284-9] [PMID: 31375757]
[3]
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75(6): 1334-57.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15026] [PMID: 32370572]
[4]
Koracevic G, Micic S, Stojanovic M, et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol 2021; 19(4): 343-6.
[http://dx.doi.org/10.2174/1570161118666200518113833] [PMID: 32418526]
[5]
Diaconu CC, Marcu DR, Bratu OG, et al. Beta-blockers in cardiovascular therapy: A Review. J Mind Med Sci 2019; 6(2): 216-23.
[http://dx.doi.org/10.22543/7674.62.P216223]
[6]
Koracevic G, Micic S, Stojanovic M, et al. Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies. Hypertens Res 2020; 43(7): 591-6.
[http://dx.doi.org/10.1038/s41440-020-0449-6] [PMID: 32382156]
[7]
Patel PH, Nguyen M, Rodriguez R, Surani S, Udeani G. Omecamtiv mecarbil: A novel mechanistic and therapeutic approach to chronic heart failure management. Cureus 2021; 13(1): e12419.
[http://dx.doi.org/10.7759/cureus.12419] [PMID: 33542867]
[8]
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407-77.
[http://dx.doi.org/10.1093/eurheartj/ehz425] [PMID: 31504439]
[9]
van Diepen S, Armstrong PW. Learning whether to subtract beta-blockers: It’s about time. Eur Heart J 2021; 42(9): 915-8.
[http://dx.doi.org/10.1093/eurheartj/ehaa1033] [PMID: 33428708]
[10]
Shitara J, Naito R, Kasai T, et al. Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction. BMC Cardiovasc Disord 2021; 21(1): 36.
[http://dx.doi.org/10.1186/s12872-021-01850-9] [PMID: 33446110]
[11]
Volpe M, Mastromarino V, Santolamazza C. Historical overview: Beta-Blockers in hypertension and cardiovascular disease. Springer Healthcare Italia 2019.
[12]
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: The future of treatment. Eur J Heart Fail 2020; 22(2): 228-40.
[http://dx.doi.org/10.1002/ejhf.1715] [PMID: 31919938]
[13]
Antunes MO, Scudeler TL. Hypertrophic cardiomyopathy. Int J Cardiol Heart Vasc 2020; 27: 100503.
[http://dx.doi.org/10.1016/j.ijcha.2020.100503] [PMID: 32309534]
[14]
Farzam K, Jan A. Beta Blockers. Treasure Island, FL: StatPearls Publishing 2020.
[15]
Scottish Intercollegiate Guidelines Network (SIGN). Management of stable angina. Edinburgh: SIGN; 2018. (SIGN publication no. 151). 2018. Available from: http://www.sign.ac.uk
[16]
Tucker WD, Sankar P, Kariyanna T. Selective Beta-1-Blockers. Treasure Island, FL: StatPearls Publishing 2021.
[17]
Garcia-Tsao G. The use of nonselective beta blockers for treatment of portal hypertension. Gastroenterol Hepatol (N Y) 2017; 13(10): 617-9.
[PMID: 29230139]
[18]
Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis 2017; 12: 3041-6.
[http://dx.doi.org/10.2147/COPD.S144333] [PMID: 29089752]
[19]
Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: The good, the bad and the ugly. Curr Opin Pulm Med 2021; 27(2): 125-31.
[http://dx.doi.org/10.1097/MCP.0000000000000748] [PMID: 33332878]
[20]
Bakris G, Ali W, Parati G. ACC/AHA versus ESC/ESH on hypertension guidelines: Jacc guideline comparison. J Am Coll Cardiol 2019; 73(23): 3018-26.
[http://dx.doi.org/10.1016/j.jacc.2019.03.507] [PMID: 31196460]
[21]
Mancia G. β-Blockers and Guidelines Beta-blockers in hypertension and cardiovascular disease. Springer Healthcare Italia 2019.
[22]
Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Res 2021; 7(1): 00801-2020.
[http://dx.doi.org/10.1183/23120541.00801-2020] [PMID: 33681344]
[23]
Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of ran-domized controlled trials. Sci Rep 2021; 11(1): 452.
[http://dx.doi.org/10.1038/s41598-020-79837-3] [PMID: 33432057]
[24]
Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarc-tion without reduced ejection fraction: Study protocol for a randomized controlled trial. Trials 2020; 21(1): 415.
[http://dx.doi.org/10.1186/s13063-020-4214-6] [PMID: 32446298]
[25]
Rhee MY, Kim CH, Ahn Y, et al. Efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia. Drug Des Devel Ther 2020; 14: 5005-17.
[http://dx.doi.org/10.2147/DDDT.S280055] [PMID: 33235439]
[26]
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591]
[27]
Koracevic G, Micic S, Stojanovic M. By discontinuing beta-blockers before an exercise test we may precipitate a rebound phenomenon. Curr Vasc Pharmacol 2021; 19(6): 624-33. [e-pub ahead of print]
[http://dx.doi.org/10.2174/1570161119666210302152322] [PMID: 33653252]
[28]
Singh S, Ricardo-Silgado ML, Bielinski SJ, Acosta A. Pharmacogenomics of medication-induced weight gain and antiobesity medications. Obesity (Silver Spring) 2021; 29(2): 265-73.
[http://dx.doi.org/10.1002/oby.23068] [PMID: 33491309]
[29]
Desta L, Khedri M, Jernberg T, et al. Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction. ESC Heart Fail 2021; 8(1): 344-55.
[http://dx.doi.org/10.1002/ehf2.13079] [PMID: 33259148]
[30]
Andersson C, Shilane D, Go AS, et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 2014; 64(3): 247-52.
[http://dx.doi.org/10.1016/j.jacc.2014.04.042] [PMID: 25034059]
[31]
Thome J, David Byon D. Addressing hypoglycemic emergencies. US Pharm 2018; 43(10): HS2-6.
[32]
Beattie WS, Hare GM. Beta-blockers are the old BLACK. Can J Anesth/J can d'anesth 2014; 61(9): 787-93.
[http://dx.doi.org/10.1007/s12630-014-0199-5]
[33]
Noyes R Jr. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am 1985; 8(1): 119-32.
[http://dx.doi.org/10.1016/S0193-953X(18)30713-5] [PMID: 2859576]
[34]
Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev 2014; (9): CD004476.
[http://dx.doi.org/10.1002/14651858.CD004476.pub2]
[35]
Fragata J. Beta-blockers: Protective against perioperative stress, but not for all - as the evidence shows. Rev Port Cardiol 2019; 38(10): 695-6.
[http://dx.doi.org/10.1016/j.repce.2020.01.003] [PMID: 31964556]
[36]
Bellis A, Mauro C, Barbato E, Ceriello A, Cittadini A, Morisco C. Stress-induced hyperglycaemia in non-diabetic patients with acute coronary syndrome: From molecular mechanisms to new therapeutic perspectives. Int J Mol Sci 2021; 22(2): 775.
[http://dx.doi.org/10.3390/ijms22020775] [PMID: 33466656]
[37]
Prasad Hrishi A, Ruby Lionel K, Prathapadas U. Head rules over the heart: Cardiac manifestations of cerebral disorders. Indian J Crit Care Med 2019; 23(7): 329-35.
[http://dx.doi.org/10.5005/jp-journals-10071-23208] [PMID: 31406441]
[38]
Jørgensen ME, Andersson C, Venkatesan S, Sanders RD. Beta-blockers in noncardiac surgery: Did observational studies put us back on safe ground? Br J Anaesth 2018; 121(1): 16-25.
[http://dx.doi.org/10.1016/j.bja.2018.02.004] [PMID: 29935568]
[39]
Pham D, Ward H, Yong B, et al. Is lactate lower in septic patients who are prescribed beta blockers? Retrospective cohort study of an intensive care population. Emerg Med Australas 2021; 33(1): 82-7.
[http://dx.doi.org/10.1111/1742-6723.13584] [PMID: 32808473]
[40]
Guz D, Buchritz S, Guz A, et al. Beta-Blockers, tachycardia and survival following sepsis-an observational cohort study. Clin Infect Dis 2021; ciab034.
[http://dx.doi.org/10.1093/cid/ciab034]
[41]
Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: A systematic review. Br J Anaesth 2018; 121(4): 706-21.
[http://dx.doi.org/10.1016/j.bja.2018.04.036] [PMID: 30236233]
[42]
Donaldson J, Haddad B, Khan WS. The pathophysiology, diagnosis and current management of acute compartment syndrome. Open Orthop J 2014; 8(1): 185-93.
[http://dx.doi.org/10.2174/1874325001408010185] [PMID: 25067973]
[43]
Salmasi V, Maheshwari K, Yang D, et al. Relationship between intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after noncardiac surgery: A retrospective cohort analysis. Anesthesiology 2017; 126(1): 47-65.
[http://dx.doi.org/10.1097/ALN.0000000000001432] [PMID: 27792044]
[44]
Brady KM, Hudson A, Hood R, DeCaria B, Lewis C, Hogue CW. Personalizing the definition of hypotension to protect the brain. Anesthesiology 2020; 132(1): 170-9.
[http://dx.doi.org/10.1097/ALN.0000000000003005] [PMID: 31644437]
[45]
Ziegler MG. Atherosclerosis and blood pressure variability. Hypertension 2018; 71(3): 403-5.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10481] [PMID: 29295854]
[46]
Kong Q, Ma X, Wang C, Du X, Ren Y, Wan Y. Total atherosclerosis burden of baroreceptor-resident arteries independently predicts blood pressure dipping in patients with ischemic stroke. Hypertension 2020; 75(6): 1505-12.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15036] [PMID: 32336234]
[47]
Bhalke RD, Giri MA, Anil RY, Balasaheb NM, Nanasaheb PA, Pande VV. Hypotension: A comprehensive review. J Pharmacogn Phytochem 2021; 10(1): 1945-7.
[48]
Lundqvist MH, Almby K, Wiklund U, et al. Altered hormonal and autonomic nerve responses to hypo- and hyperglycaemia are found in overweight and insulin-resistant individuals and may contribute to the development of type 2 diabetes. Diabetologia 2021; 64(3): 641-55.
[http://dx.doi.org/10.1007/s00125-020-05332-z] [PMID: 33241460]
[49]
Sejling AS, Wang P, Zhu W, et al. Repeated activation of noradrenergic receptors in the ventromedial hypothalamus suppresses the re-sponse to hypoglycemia. Endocrinology 2021; 162(3): bqaa241.
[http://dx.doi.org/10.1210/endocr/bqaa241]
[50]
Sheehan A, Patti ME. Hypoglycemia after upper gastrointestinal surgery: Clinical approach to assessment, diagnosis, and treatment. Diabetes Metab Syndr Obes 2020; 13: 4469-82.
[http://dx.doi.org/10.2147/DMSO.S233078] [PMID: 33239898]
[51]
Koraćević G, Mićić S, Stojanović M, et al. Single prognostic cutoff value for admission glycemia in acute myocardial infarction has been used although high-risk stems from hyperglycemia as well as from hypoglycemia (a narrative review). Prim Care Diabetes 2020; 14(6): 594-604.
[http://dx.doi.org/10.1016/j.pcd.2020.09.004] [PMID: 32988774]
[52]
Simsek Y, Karaca Z, Diri H, Tanriverdi F, Unluhizarci K, Kelestemur F. Is biochemical hypoglycemia necessary during an insulin toler-ance test? Arch Endocrinol Metab 2020; 64(1): 82-8.
[http://dx.doi.org/10.20945/2359-3997000000200] [PMID: 32187262]
[53]
Sharma S, Hashmi MF, Bhattacharya PT. Hypotension. Treasure Island, FL: StatPearls Publishing 2021.
[54]
Chen Z, Shao DH, Ma XD, Mao ZM. Dexmedetomidine aggravates hypotension following mesenteric traction during total gastrectomy: A randomized controlled trial. Ann Saudi Med 2020; 40(3): 183-90.
[http://dx.doi.org/10.5144/0256-4947.2020.183] [PMID: 32493029]
[55]
Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72(11): 1294-309.
[http://dx.doi.org/10.1016/j.jacc.2018.05.079] [PMID: 30190008]
[56]
Goldstein DS. Catecholamines and stress. Endocr Regul 2003; 37(2): 69-80.
[PMID: 12932192]
[57]
Thau L, Gandhi J, Sharma S. Physiology, Cortisol. Treasure Island, FL: StatPearls Publishing 2021.
[58]
Mokrousov IS, Perfilova VN, Prokofiev II, et al. Effect of a new cyclic derivative of GABA, RGPU-207, on the functions of cardiac and cerebral mitochondria of stressed animals. J Pharm Pharmacol 2019; 71(7): 1055-64.
[http://dx.doi.org/10.1111/jphp.13086] [PMID: 30864160]
[59]
Long C, Dungan K. Hypoglycemia awareness and burden among hospitalized patients at high risk for hypoglycemia. J Diabetes Complications 2020; 34(4): 107521.
[http://dx.doi.org/10.1016/j.jdiacomp.2019.107521] [PMID: 31937469]
[60]
Laurent S. Antihypertensive drugs. Pharmacol Res 2017; 124: 116-25.
[http://dx.doi.org/10.1016/j.phrs.2017.07.026] [PMID: 28780421]
[61]
Ecks S. Depression, deprivation, and dysbiosis: Polyiatrogenesis in multiple chronic illnesses. Cult Med Psychiatry 2021; 45(4): 507-24. [e-pub ahead of print]
[http://dx.doi.org/10.1007/s11013-020-09699-x] [PMID: 33547618]
[62]
Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc Diabetol 2019; 18(1): 163.
[http://dx.doi.org/10.1186/s12933-019-0967-1] [PMID: 31775749]
[63]
Makin S, Stott DJ. Managing blood pressure in older adults. BMJ 2018; 362: k2912.
[http://dx.doi.org/10.1136/bmj.k2912] [PMID: 29980562]
[64]
Rhyu YA, Jang JY, Park S, et al. Impaired cortisol and growth hormone counterregulatory responses among severe hypoglycemic pa-tients with type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2019; 34(2): 187-94.
[http://dx.doi.org/10.3803/EnM.2019.34.2.187] [PMID: 31257746]
[65]
Lager I, Jagenburg R, von Schenck H, Smith U. Effect of beta-blockade on hormone release during hypoglycaemia in insulin-dependent diabetics. Acta Endocrinol (Copenh) 1980; 95(3): 364-71.
[http://dx.doi.org/10.1530/acta.0.0950364] [PMID: 6108035]
[66]
Bokhari S, Plummer E, Emmerson P, Gupta A, Meyer C. Glucose counterregulation in advanced type 2 diabetes: Effect of β-adrenergic blockade. Diabetes Care 2014; 37(11): 3040-6.
[http://dx.doi.org/10.2337/dc14-0782] [PMID: 25092686]
[67]
Kerr D, MacDonald IA, Heller SR, Tattersall RB. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990; 29(6): 685-93.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03689.x] [PMID: 1974143]
[68]
Clausen-Sjöbom N, Lins PE, Adamson U, Curstedt T, Hamberger B. Effects of metoprolol on the counter-regulation and recognition of prolonged hypoglycemia in insulin-dependent diabetics. Acta Med Scand 1987; 222(1): 57-63.
[http://dx.doi.org/10.1111/j.0954-6820.1987.tb09929.x] [PMID: 3307308]
[69]
Coop CA, Schapira RS, Freeman TM, Are ACE. Inhibitors and beta-blockers dangerous in patients at risk for anaphylaxis? J Allergy Clin Immunol Pract 2017; 5(5): 1207-11.
[http://dx.doi.org/10.1016/j.jaip.2017.04.033] [PMID: 28552379]
[70]
Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: Epidemiology, prognosis, and treatment. J Am Coll Cardiol 2015; 66(7): 848-60.
[http://dx.doi.org/10.1016/j.jacc.2015.06.1084] [PMID: 26271068]
[71]
Perez CM, Hazari MS, Farraj AK. Role of autonomic reflex arcs in cardiovascular responses to air pollution exposure. Cardiovasc Toxicol 2015; 15(1): 69-78.
[http://dx.doi.org/10.1007/s12012-014-9272-0] [PMID: 25123706]
[72]
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM. Cochrane corner: Beta-blockers for hypertension. Heart 2018; 104(4): 282-3.
[http://dx.doi.org/10.1136/heartjnl-2017-311585] [PMID: 28756403]
[73]
Holm H, Ricci F, Di Martino G, et al. Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. Vascul Pharmacol 2020; 125-126: 106649.
[http://dx.doi.org/10.1016/j.vph.2020.106649] [PMID: 31958512]
[74]
Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British Women’s Heart and Health Study. Age Ageing 2010; 39(1): 51-6.
[http://dx.doi.org/10.1093/ageing/afp192] [PMID: 19897539]
[75]
BISOPROLOL SANDOZ® (bisoprolol fumarate) Consumer Medicine Information (leaflet revised in March 2021). Sandoz Pty Ltd. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-CMI-01404-3&d=202103311016933
[76]
APO-Bisoprolol (Bisoprolol fumarate) Consumer Medicine Information (Leaflet updated in 2020). Apotex Inc. Available from: https://media.healthdirect.org.au/medicines/GuildLink_Information/182114/CMI/txcbisop10720.pdf
[77]
Bisoprolol HCT STADA (Bisoprolol/ Hydrochlorothiazide) Package leaflet: Information for the user (2020). STADA Arzneimittel AG. Available from: https://file.wuxuwang.com/hma/BE_H_0126_001_FinalPL.pdf
[78]
Bisoprolol Mylan (bisoprolol fumarate) Package leaflet: Information for the patient. Mylan 2019. Available from: https://www.hpra.ie/img/uploaded/swedocuments/064e8a00-7872-48a0-b0e7-88d2698293cc.pdf
[79]
Bisoprolol generichealth (bisoprolol fumarate) Consumer medicine information. Generic Health 2020. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-CMI-02590-1&d=202103301016933
[80]
BISOPROLOL SANDOZ® (bisoprolol fumarate) Consumer Medicine Information (Leaflet revised in2011). Sandoz Pty Ltd. Available from: https://gp2u.com.au/static/pdf/B/BISOPROLOL_SANDOZ-CMI.pdf
[81]
Bisoprolol Medication Information Leaflet. National Medication Information workgroup. The workgroup consists of cluster partners (National Healthcare Group, National University Health System and SingHealth), community pharmacies (Guardian, Unity and Watsons) and Pharmaceutical Society of Singapore 2019. Available from: https://www.ttsh.com.sg/Patients/and/Visitors/Medical/Services/Pharmacy/Documents/Pharmacy/PIL/PIL%20by%20Drug/Bisoprolol.pdf
[82]
MINAX XL (metoprolol succinate) Consumer medicine information (2020). Alphapharm Pty Ltd, Mylan Inc. Available from: https://media.healthdirect.org.au/medicines/GuildLink_Information/205151/CMI/afcminxl10120.pdf
[83]
Metocor (metoprolol tartrate) Package leaflet: Information for the user (2019). Rowex Ltd. Available from: http://rowex.ie/wp-content/uploads/2019/10/Metocor-50mg-100mg-Tablets-Leaflet.pdf
[84]
TOPROL-XL™ (Metoprolol succinate) Consumer Medicine Information. AstraZeneca 2017. Available from: https://www.news-medical.net/drugs/Toprol-XL.aspx
[85]
Metoprolol tartrate. Package leaflet: Information for user (2019). Accord Healthcare Ltd. Available from: https://www.medicines.org.uk/emc/files/pil.5344.pdf
[86]
Metoprolol Sandoz® (Metoprolol tartrate). Consumer Medicine Information. Published by MIMS 2020. Available from: https://www.nps.org.au/medicine-finder/metoprolol-sandoz-tabletshttps://www.nps.org.au/assets/medicines/9e051f05-976d-4697-a2d9-a53300ff8020-reduced.pdf
[87]
Bloxazoc (Metoprolol succinate) Package leaflet: Information for the user (2015). KRKA, d.d. Available from: https://www.ravimiregister.ee/Data/PIL_ENG/PIL_31809_ENG.pdf
[88]
Carvedilol Package leaflet: Information for the user (2019) Milpharm Limited. Available from: https://www.medicines.org.uk/emc/files/pil.3105.pdf
[89]
Carvedilol Package leaflet: Information for the patient (2019) Mylan. Available from: https://www.medicines.org.uk/emc/files/pil.2547.pdf
[90]
Carvedilol Apotex (carvedilol) Package leaflet: Information for the user (2014) Apotex. Available from: http://mri.ctsmrp.eu/download/NL_H_1633_002_FinalPI_2of4.pdf
[91]
AURO-CARVEDILOL (carvedilol) Product monograph; consumer information (2013). Auro Pharma Inc. Available from: http://www.auropharma.ca/products/monograph/Auro-Carvedilol-PM.pdf
[92]
Carvedilol Patient information (2010). Dr. Reddy’s available from: https://www.drreddys.com/media/102860/carvedilol_tablets_usp.pdf
[93]
Nebimel (Nebivolol) Package leaflet: Information for the user (revised in 2020). Clonmel Healthcare Ltd. Available from: https://www.hpra.ie/img/uploaded/swedocuments/7c917f77-c72f-41c1-a67e-b93fcdbb1301.pdf
[94]
Nebivolol Package leaflet: Information for the user (2019). Glenmark Pharmaceuticals Europe Ltd. Available from: https://www.medicines.org.uk/emc/files/pil.9966.pdf
[95]
BYSTOLIC® (Nebivolol) Product Monograph. Patient medication information. 2018; 31-5.
[96]
Nebivolol (as hydrochloride) Package leaflet: Information for the user (2018). Glenmark Pharmaceuticals Europe Ltd. Available from: https://www.medicines.org.uk/emc/files/pil.9967.pdf
[97]
Nebivolol Mercury (nebivolol) Package leaflet: Information for the patient (revised in 2017). Mercury Pharmaceuticals Ltd available from: https://mri.cts-mrp.eu/human/downloads/DE_H_3840_002_FinalPI_4of4.pdf
[98]
Nelet (nebivolol) Package leaflet: Information for the patient (last revised 2017). McDermott Laboratories Ltd. Available from: https://www.hpra.ie/img/uploaded/swedocuments/PIL-2190766-16062017153500-636332241219218750.pdf
[99]
BYSTOLIC® (nebivolol) Highlights of prescribing information (revised 2011). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021742s013lbl.pdf
[100]
Inderal (propranolol hydrochloride) Package leaflet: Information for the user. AstraZeneca 2018. Available from: https://www.hpra.ie/img/uploaded/swedocuments/92ca6acd-c10b-40f8-b0b9-0f311184dad3.pdf
[101]
INDERAL-LA (Propranolol Hydrochloride) Product Monograph. Consumer information. 2016; 28-30.
[102]
Propranolol (Propranolol hydrochloride) Consumer Medicine Information. Apotex Pty Ltd 2018. Available from: https://media.healthdirect.org.au/medicines/GuildLink_Information/222958/CMI/txcpropr10818.pdf
[103]
APO-Propranolol Tablets (Propranolol hydrochloride) Consumer Medicine Information. Published by MIMS 2018. Available from: https://www.nps.org.au/medicinefinder/apopropranololtabletshttps://www.nps.org.au/assets/medicines/1ffdb754-3ac1-4700-ae32-a53300ffb615-reduced.pdf
[104]
Hemangiol (Propranolol) Consumer Medicine Information. Published by MIMS 2018. Available from: https://www.nps.org.au/assets/medicines/264c08ba-eaf5-42fa-a42e-a77000ea8ce8-reduced.pdf
[105]
Propranolol (Propranolol hydrochloride) Package leaflet: Information for the user. Accord Healthcare. 2020. Available from: https://www.medicines.org.uk/emc/files/pil.2903.pdf
[106]
Carvedilol phosphate Patient information. Sun Pharmaceutical Industries, Inc. 2017. Available from: https://www.sunpharma.com/sites/default/files/carvedilol-er-capsules-pil-090132.pdf
[107]
Bönhof GJ, Herder C, Ziegler D. Diagnostic tools, biomarkers, and treatments in diabetic polyneuropathy and cardiovascular autonomic neuropathy. Curr Diabetes Rev 2022; 18(5): e120421192781.
[http://dx.doi.org/10.2174/1573399817666210412123740] [PMID: 33845748]
[108]
Cohen-Hagai K, Fanadka F, Grumberg T, Topaz G, Nacasch N, Greenberg M, et al. Diastolic blood pressure is associated with brain atrophy in hemodialysis patients: A single center case-control study. Ther Apher Dial 2022; 26: 94-102.
[http://dx.doi.org/10.1111/1744-9987.13647] [PMID: 33763913]
[109]
Guyenet PG, Stornetta RL. Rostral ventrolateral medulla, retropontine region and autonomic regulations. Auton Neurosci 2022; 237: 102922.
[http://dx.doi.org/10.1016/j.autneu.2021.102922] [PMID: 34814098]
[110]
Grotle AK, Macefield VG, Farquhar WB, O’Leary DS, Stone AJ. Recent advances in exercise pressor reflex function in health and dis-ease. Auton Neurosci 2020; 228: 102698.
[http://dx.doi.org/10.1016/j.autneu.2020.102698] [PMID: 32861944]
[111]
Min S, Chang RB, Prescott SL, et al. Arterial baroreceptors sense blood pressure through decorated aortic claws. Cell Rep 2019; 29(8): 2192-201.
[http://dx.doi.org/10.1016/j.celrep.2019.10.040] [PMID: 31747594]
[112]
Ghitani N, Chesler AT. The anatomy of the baroreceptor reflex. Cell Rep 2019; 29(8): 2121-2.
[http://dx.doi.org/10.1016/j.celrep.2019.11.031] [PMID: 31747586]
[113]
Shah-Becker S, Pennock M, Sinoway L, Goldenberg D, Goyal N. Baroreceptor reflex failure: Review of the literature and the potential impact on patients with head and neck cancer. Head Neck 2017; 39(10): 2135-41.
[http://dx.doi.org/10.1002/hed.24857] [PMID: 28675547]
[114]
Lauer MS. Heart rate recovery: Coming back full-circle to the baroreceptor reflex. Circ Res 2016; 119(5): 582-3.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309392] [PMID: 27539969]
[115]
Silvani A, Calandra-Buonaura G, Benarroch EE, Dampney RA, Cortelli P. Bidirectional interactions between the baroreceptor reflex and arousal: An update. Sleep Med 2015; 16(2): 210-6.
[http://dx.doi.org/10.1016/j.sleep.2014.10.011] [PMID: 25616389]
[116]
Reyes del Paso GA, Montoro C, Muñóz Ladrón de Guevara C, Duschek S, Jennings JR. The effect of baroreceptor stimulation on pain perception depends on the elicitation of the reflex cardiovascular response: Evidence of the interplay between the two branches of the baroreceptor system. Biol Psychol 2014; 101: 82-90.
[http://dx.doi.org/10.1016/j.biopsycho.2014.07.004] [PMID: 25038302]
[117]
Verberne AJ, Sabetghadam A, Korim WS. Neural pathways that control the glucose counterregulatory response. Front Neurosci 2014; 8: 38.
[http://dx.doi.org/10.3389/fnins.2014.00038] [PMID: 24616659]
[118]
Winkler Z, Kuti D, Polyák Á, et al. Hypoglycemia-activated hypothalamic microglia impairs glucose counterregulatory responses. Sci Rep 2019; 9(1): 6224.
[http://dx.doi.org/10.1038/s41598-019-42728-3] [PMID: 30996341]
[119]
Nedoboy PE, Cohen M, Farnham MM. Slow but steady-the responsiveness of sympathoadrenal system to a hypoglycemic challenge in ketogenic diet-fed rats. Nutrients 2021; 13(8): 2627.
[http://dx.doi.org/10.3390/nu13082627] [PMID: 34444787]
[120]
Mulkey SB, Plessis AD. The critical role of the central autonomic nervous system in fetal-neonatal transition. Semin Pediatr Neurol 2018; 28: 29-37.
[http://dx.doi.org/10.1016/j.spen.2018.05.004] [PMID: 30522725]
[121]
Belfort-DeAguiar R, Gallezot JD, Hwang JJ, et al. Noradrenergic activity in the human brain: A mechanism supporting the defense against hypoglycemia. J Clin Endocrinol Metab 2018; 103(6): 2244-52.
[http://dx.doi.org/10.1210/jc.2017-02717] [PMID: 29590401]
[122]
Kakall ZM, Kavurma MM, Cohen EM, Howe PR, Nedoboy PE, Pilowsky PM. Repetitive hypoglycemia reduces activation of glucose-responsive neurons in C1 and C3 medullary brain regions to subsequent hypoglycemia. Am J Physiol Endocrinol Metab 2019; 317(2): E388-98.
[http://dx.doi.org/10.1152/ajpendo.00051.2019] [PMID: 31013147]
[123]
Güemes A, Georgiou P. Review of the role of the nervous system in glucose homoeostasis and future perspectives towards the manage-ment of diabetes. Bioelectron Med 2018; 4(1): 9.
[http://dx.doi.org/10.1186/s42234-018-0009-4] [PMID: 32232085]
[124]
López-Gambero AJ, Martínez F, Salazar K, Cifuentes M, Nualart F. Brain glucose-sensing mechanism and energy homeostasis. Mol Neurobiol 2019; 56(2): 769-96.
[http://dx.doi.org/10.1007/s12035-018-1099-4] [PMID: 29796992]
[125]
Raman PG. Central nervous system control of glucose homeostasis. Open J Endocr Metab Dis 2017; 7(12): 227-34.
[http://dx.doi.org/10.4236/ojemd.2017.712020]
[126]
Stanley S, Moheet A, Seaquist ER. Central mechanisms of glucose sensing and counterregulation in defense of hypoglycemia. Endocr Rev 2019; 40(3): 768-88.
[http://dx.doi.org/10.1210/er.2018-00226] [PMID: 30689785]
[127]
Oshima N, Onimaru H, Matsubara H, et al. Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ven-trolateral medulla in neonatal Wistar rats. Neuroscience 2017; 344: 74-88.
[http://dx.doi.org/10.1016/j.neuroscience.2016.12.039] [PMID: 28062192]
[128]
Zhao Z, Wang L, Gao W, et al. A central catecholaminergic circuit controls blood glucose levels during stress. Neuron 2017; 95(1): 138-152.e5.
[http://dx.doi.org/10.1016/j.neuron.2017.05.031] [PMID: 28625488]
[129]
Kumagai H, Oshima N, Matsuura T, et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res 2012; 35(2): 132-41.
[http://dx.doi.org/10.1038/hr.2011.208] [PMID: 22170390]
[130]
Korim WS, Bou Farah L, McMullan S, Verberne AJ. Orexinergic activation of medullary premotor neurons modulates the adrenal sym-pathoexcitation to hypothalamic glucoprivation. Diabetes 2014; 63(6): 1895-906.
[http://dx.doi.org/10.2337/db13-1073] [PMID: 24550189]
[131]
Korim WS, Llewellyn-Smith IJ, Verberne AJ. Activation of medulla-projecting perifornical neurons modulates the adrenal sympathetic response to hypoglycemia: Involvement of orexin type 2 (OX2-R) receptors. Endocrinology 2016; 157(2): 810-9.
[http://dx.doi.org/10.1210/en.2015-1712] [PMID: 26653571]
[132]
Espinoza L, Fedorchak S, Boychuk CR. Interplay between systemic metabolic cues and autonomic output: Connecting cardiometabolic function and parasympathetic circuits. Front Physiol 2021; 12: 624595.
[http://dx.doi.org/10.3389/fphys.2021.624595] [PMID: 33776789]
[133]
Ma Y, Wang Q, Joe D, Wang M, Whim MD. Recurrent hypoglycemia inhibits the counterregulatory response by suppressing adrenal activity. J Clin Invest 2018; 128(9): 3866-71.
[http://dx.doi.org/10.1172/JCI91921] [PMID: 30080182]
[134]
Kakall ZM, Nedoboy PE, Farnham MMJ, Pilowsky PM. Activation of µ-opioid receptors in the rostral ventrolateral medulla blocks the sympathetic counterregulatory response to glucoprivation. Am J Physiol Regul Integr Comp Physiol 2018; 315(6): R1115-22.
[http://dx.doi.org/10.1152/ajpregu.00248.2018]
[135]
Guyenet PG, Stornetta RL, Holloway BB, Souza GMPR, Abbott SBG. Rostral ventrolateral medulla and hypertension. Hypertension 2018; 72(3): 559-66.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.10921] [PMID: 30354763]
[136]
Shimazu T, Minokoshi Y. Systemic glucoregulation by glucose-sensing neurons in the Ventromedial Hypothalamic Nucleus (VMH). J Endocr Soc 2017; 1(5): 449-59.
[http://dx.doi.org/10.1210/js.2016-1104] [PMID: 29264500]
[137]
Xue B, Zhang Z, Beltz TG, Guo F, Hay M, Johnson AK. Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension. Am J Physiol Heart Circ Physiol 2014; 307(2): H191-8.
[http://dx.doi.org/10.1152/ajpheart.01012.2013] [PMID: 24858844]
[138]
Witt CM, Bolona L, Kinney MO, et al. Denervation of the extrinsic cardiac sympathetic nervous system as a treatment modality for ar-rhythmia. Europace 2017; 19(7): 1075-83.
[http://dx.doi.org/10.1093/europace/eux011] [PMID: 28340164]
[139]
Hale GM, Valdes J, Brenner M. The treatment of primary orthostatic hypotension. Ann Pharmacother 2017; 51(5): 417-28.
[http://dx.doi.org/10.1177/1060028016689264] [PMID: 28092986]
[140]
Zeng WZ, Marshall KL, Min S, et al. PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex. Science 2018; 362(6413): 464-7.
[http://dx.doi.org/10.1126/science.aau6324] [PMID: 30361375]
[141]
La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: Measurement and clinical implications. Ann Noninvasive Electrocardiol 2008; 13(2): 191-207.
[http://dx.doi.org/10.1111/j.1542-474X.2008.00219.x] [PMID: 18426445]

Rights & Permissions Print Cite
Article Metrics
28
1
World Health Day
© 2024 Bentham Science Publishers | Privacy Policy